Medicine and Dentistry
Patient
100%
Fatty Liver
52%
Therapeutic Procedure
47%
Chronic Hepatitis B
39%
Alcohol Consumption
36%
Hepatitis B Antigen
32%
Combination Therapy
24%
Liver Cirrhosis
22%
Gastroenterology
22%
Hepatitis B(e) Antigen
22%
Hazard Ratio
20%
Mortality
19%
Fibrosis
19%
Follow up
19%
Continuous Renal Replacement Therapy
19%
Liver Fibrosis
18%
Alpha 1 Antitrypsin
18%
Survival
15%
Septic Shock
15%
Intensive Care Unit
15%
COVID-19
13%
Liver Injury
13%
RNA
12%
Lactic Acid
11%
Inpatient
11%
Hepatocellular Carcinoma
10%
All Cause Mortality
9%
Infection
9%
Protein
9%
Age
9%
Genotype
9%
Liver
8%
Adverse Outcome
8%
Odds Ratio
7%
Hepatitis B
7%
Steatohepatitis
7%
Biological Marker
7%
Analysis
7%
Liver Biopsy
6%
Hepatitis B Virus
6%
Association
6%
Death
5%
Steatosis
5%
Serum
5%
Risk Stratification
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fatty Liver
27%
Liver Cirrhosis
22%
Hepatitis B Surface Antigen
19%
Chronic Hepatitis B
18%
Liver Fibrosis
18%
Alpha 1 Antitrypsin
18%
Fibrosis
17%
Hepatitis B(e) Antigen
14%
Liver Injury
13%
Animal
9%
Human
9%
Mouse
9%
Protein
9%
Hepatitis B
7%
Hepatitis B Virus
6%
All Cause Mortality
5%
Immunology and Microbiology
Liver
37%
HBsAg
35%
Hepatitis B Virus
35%
Hepatitis B
24%
Peginterferon Alpha
22%
Hepatitis B(e) Antigen
9%
Human
9%
Mouse
9%
Animal
9%
Time
6%
Genotype
5%
Association
5%